05:55 AM EDT, 05/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our EPADS estimates to DKK26.70 from DKK27.90 for 2025 and to DKK32.10 from DKK32.90 for 2026 in view of the guidance cut, while our target price of USD64 remains unchanged at a 2025 P/E of 15.9x. NOVO lowers its 2025 outlook, now guiding for 13%-21% sales growth and 16%-24% operating profit growth (CER), down from previous guidance of 16%-24% and 19%-27%, respectively, citing the impact of compounded GLP-1s, which hit Wegovy's sales in Q1 2025. Following the FDA's removal of semaglutide from drug shortage lists, NOVO expects compounded GLP-1 usage to decline in H2 2025. We believe upcoming trial results for CagriSema and amycretin, will be key catalysts for NOVO's continued dominance in the obesity market, while Wegovy's inclusion as the preferred GLP-1 medicine in CVS Caremark's largest commercial template formularies from July 1, could help to expand the access to the drug.